Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anavex Life Sciences

8.95
+0.11001.24%
Post-market: 8.90-0.0500-0.56%19:03 EDT
Volume:350.84K
Turnover:3.11M
Market Cap:761.32M
PE:-16.20
High:8.99
Open:8.81
Low:8.70
Close:8.84
Loading ...

Anavex Life Sciences Announces Submission of Blarcamesine Maa for Treatment of Alzheimer’s Disease to Ema

THOMSON REUTERS
·
26 Nov 2024

D. Boral says Anavex Alzheimer’s approach superior to Cassava

TIPRANKS
·
25 Nov 2024

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
25 Nov 2024

BRIEF-Anavex Life Sciences Announces Acceptance Of Peer-Reviewed Manuscript

Reuters
·
25 Nov 2024

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase Iib/Iii Data in a Reference Alzheimer’s Disease Journal

THOMSON REUTERS
·
25 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
21 Nov 2024

Anavex Life Sciences Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Nov 2024

Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion

TIPRANKS
·
04 Nov 2024

Anavex Life Sciences’ Promising Alzheimer’s Drug: Buy Rating Justified by Positive Clinical Outcomes and Strategic Advantages

TIPRANKS
·
31 Oct 2024

Anavex Life Sciences Is Maintained at Buy by EF Hutton

Dow Jones
·
31 Oct 2024

Anavex gains as lead asset slows Alzheimer’s disease progression by a third

seekingalpha
·
31 Oct 2024

Anavex’s Blarcamesine Achieves Pre-Specified Efficacy in Phase Iib/Iii Alzheimer’s Trial: Data Presented at Ctad Conference 2024

THOMSON REUTERS
·
31 Oct 2024

Anavex Life Sciences Corp - Regulatory Submission of Blarcamesine in Europe Expected This Quarter

THOMSON REUTERS
·
31 Oct 2024

Anavex Life Sciences Corp - Blarcamesine Slows Clinical Progression by 36.3% Over 48 Weeks

THOMSON REUTERS
·
31 Oct 2024